SM
ASMB icon

SG3 Management’s Assembly Biosciences ASMB Stock Holding History

SG3 Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-833
Closed -$39K – 981
2021
Q2 		$39K Buy
+833
New +$41.3K ﹤0.01% 947

Other funds holding ASMB

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

SG3 Management's ASMB Position: Q3 2021 in Review

SG3 Management sold out of Assembly Biosciences (ASMB) in Q3 2021, closing a stake of 833 shares — an estimated $39K sold.

SG3 Management first reported a position in ASMB in Q2 2021 and held it in 1 quarter. The position peaked at $39K in Q2 2021. 65 funds tracked by Wall St. Rank hold ASMB as of Q3 2021.

  • SG3 Management reported no remaining Assembly Biosciences position as of Q3 2021 after selling out during the quarter.
  • SG3 Management sold 833 Assembly Biosciences shares in Q3 2021, an estimated $39K.
  • SG3 Management first reported a position in Assembly Biosciences in Q2 2021 and held it in 1 quarter.
  • SG3 Management's Assembly Biosciences position peaked at $39K in Q2 2021.
  • 65 funds tracked by Wall St. Rank held Assembly Biosciences as of Q3 2021.

Based on SG3 Management's 13F filing for Q3 2021, filed 15 Nov 2021.